Methods for dynamic visualization of clinical parameters over time

1. A method for assessing a subject's ability to generate thrombin, the method comprising the steps of:

(a) obtaining a thrombin generation profile of the subject from measurements of the concentrations of factors II, V, VII/VIIa, VIII, IX, and X, tissue factor pathway inhibitor (TFPI), protein C (PC), and antithrombin (AT) in a biological sample from the subject; and

(b) displaying the thrombin generation profile in a visual form,

wherein the thrombin generation profile comprises the parameters: maximum level of thrombin generation, maximum rate of thrombin generation, total thrombin generated, and clot time;

wherein the measurements of factors II, V, VII/VIIa, VIII, IX, and X, TFPI, PC, and AT are used to derive said parameters for the thrombin generation profile,

wherein a thrombin generation profile comprising a greater than 3-fold decrease in clot time and greater than 3-fold increase in maximum level of thrombin generation, maximum rate of thrombin generation, and total thrombin generated, relative to a respective reference for each of said parameters comprising the thrombin generation profile, indicates a propensity of the subject for blood clotting; and

wherein a thrombin generation profile comprising a greater than 3-fold increase in clot time and a greater than 3-fold decrease in maximum level of thrombin generation, maximum rate of thrombin generation, and total thrombin generated, relative to the respective reference for each of said parameters comprising the thrombin generation profile, indicates a propensity of the subject for bleeding.

2. The method of claim 1 , wherein the thrombin generation profile is displayed on a display device.

3. The method of claim 2 , wherein the display device is a hand held computer, smart phone, cellular telephone, tablet computer, or personal digital assistant.

4. The method of claim 1 , wherein the parameters are clinically or computationally derived.

5. The method of claim 1 , further comprising the use of one or more measurements of biomarker levels or activity, wherein the biomarker is selected from the group consisting of activated partial thromboplastin time, blood pressure, body mass index, results of clot-based assays, clot elasticity, D-dimer and fibrin degradation product levels, euglobulin clot lysis, estrogen levels, factor V Leiden, fibrin, fibrinolysis, fibrinogen activity, genetic mutations, high density lipoprotein levels, low density lipoprotein levels, patient age, plasma composition, platelet count, platelet function, red blood cells, protein S, plasminogen, prothrombin time, prothrombin ratio, results of a thrombin generation assay, smoking status, and results obtained from a calibrated automated thrombogram, thrombogram, or thromboelastography.

6. The method of claim 1 , further comprising the use of patient data relating to bleeding score, drug dosages, drug metabolite levels, HIV status, inflammatory state, pregnancy or post-pregnancy status, and trauma.

7. The method of claim 1 , wherein the subject is identified as having hemophilia A, B, C, or von Willebrand's disease.

8. A non-transitory computer readable medium containing program instructions executable by a processor, the computer readable medium comprising:

program instructions for generating a thrombin generation profile of a subject from measurements of the concentrations of factors II, V, VII/VIIa, VIII, IX, and X, tissue factor pathway inhibitor (TFPI), protein C (PC), and antithrombin (AT) in a biological sample from the subject;

program instructions for obtaining the parameters: maximum level of thrombin generation, maximum rate of thrombin generation, total thrombin generated, and clot time, the parameters are derived from the measurements of factors II, V, VII/VIIa, VIII, IX, and X, TFPI, PC, and AT; and

program instructions for determining the propensity of the patient for blood clotting and bleeding, the determination is based on the parameters; and

program instructions for displaying the thrombin generation profile in a visual form;

wherein a thrombin generation profile comprising a greater than 3-fold decrease in clot time and greater than 3-fold increase in maximum level of thrombin generation, maximum rate of thrombin generation, and total thrombin generated, relative to a respective reference for each of said parameters comprising the thrombin generation profile, indicates a propensity of the subject for blood clotting; and

wherein a thrombin generation profile comprising a greater than 3-fold increase in clot time and a greater than 3-fold decrease in maximum level of thrombin generation, maximum rate of thrombin generation, and total thrombin generated, relative to the respective reference for each of said parameters comprising the thrombin generation profile, indicates a propensity of the subject for bleeding.

9. The non-transitory computer readable medium of claim 8 , wherein the inputting one or more measurements of biomarker levels or activity, wherein the biomarker is selected from the group consisting of activated partial thromboplastin time, blood pressure, body mass index, results of clot-based assays, clot elasticity, D-dimer and fibrin degradation product levels, CRP levels, euglobulin clot lysis, estrogen levels, fibrin, fibrinolysis, fibrinogen activity, genetic mutations, high density lipoprotein levels, light density lipoprotein levels, factor V Leiden, IL-6 levels, patient age, plasma composition, platelet count, platelet function, progesterone levels, red blood cells, protein S, plasminogen, prothrombin time, prothrombin ratio, results of a thrombin generation assay, and results obtained from a calibrated automated thrombogram, thrombogram, or thromboelastography.